Marin Independent Journal (CA)
Sept. 15--It remains unclear what if any progress San Rafael-based BioMarin Pharmaceutical has made toward helping a 45-year-old Texas woman with advanced ovarian cancer gain access to an experimental drug treatment it is developing.
BioMarin spokeswoman Debra Charlesworth said Sept. 6 the company was working with Congressman Jared Huffman to get the woman into a clinical trial. On Friday, Charlesworth said, "There has been discussion. I don't know much more beyond that. There is still ongoing dialogue."
Charlesworth said BioMarin would be providing the drug, but the trial would be run by another organization, which she declined to name. She said the other organization has not yet secured approval from the U.S. Food and Drug Administration to conduct the trial.
Paul Arden, a spokesman for Huffman, said, "Congressman Huffman is working to get both medical teams together to explore all options."
Time is short for Andrea Sloan, who was diagnosed with stage three ovarian cancer seven years ago. Her body can no longer tolerate the toxic side effects of conventional cancer treatments, and her doctors have advised that her best hope is to begin taking BioMarin's new drug -- poly ADP-ribose polymerase (PARP) inhibitor BMN 673 -- as soon as possible. The drug has produced promising results in stage-one trials.
Sloan has requested access to the drug under the FDA's "compassionate use" policy. BioMarin, however, has rejected her plea, even though -- according to Sloan -- the FDA has granted its approval. The compassionate use policy permits the use of unapproved drugs outside of clinical trials under special circumstances, but it requires the approval of the owner of the drug.
"BioMarin has not told me anything," Sloan said Thursday. "The deal with the clinical trials is a red herring, and they know it."
Sloan, executive director of the Texas Advocacy Project, an organization that provides free legal services for low-income victims of domestic violence and sexual assault, said it is highly unlikely that any researcher would add her to a trial under these circumstances.
"That is not the way the clinical trial process works. It could skew the results," she said.
In addition, Sloan said she would not be a good trial candidate because her tumor is located in an area that makes it impossible to biopsy.
Sloan said since the FDA has not even approved the trial, it could easily be another three months before it starts.
"I don't know if I'll be here in three months," she said.
Meanwhile, supporters of Sloan have mounted an aggressive social media campaign to get BioMarin to change its mind. Her story was aired on CBS News on Monday, and by Friday a petition drive on Change.org had collected more than 119,000 signatures, including those of former speaker of the House Newt Gingrich, singer Wynonna Judd, basketball star Squeaky Johnson and actresses Constance Zimmer, Ally Sheedy and Kathy Bates.
Contact Richard Halstead via e-mail at email@example.com
(c)2013 The Marin Independent Journal (Novato, Calif.)
Visit The Marin Independent Journal (Novato, Calif.) at www.marinij.com
Distributed by MCT Information Services
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.